

Sarah M Temkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5493148/publications.pdf>

Version: 2024-02-01

83
papers

2,312
citations

186209

28
h-index

233338

45
g-index

83
all docs

83
docs citations

83
times ranked

3773
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations. <i>Cancer</i> , 2022, 128, 654-664.	2.0	10
2	Gender Equity in Gynecologic Surgery: Lessons from History, Strengthening the Future. <i>Current Surgery Reports</i> , 2022, 10, 8-17.	0.4	1
3	Gynecologic Oncology and Inclusion of Women Into the Surgical Workforce: The Canary in This Coal Mine. <i>Frontiers in Oncology</i> , 2022, 12, 789910.	1.3	2
4	Reengineering academic departments of obstetrics and gynecology to operate in a pandemic world and beyond: a joint American Gynecological and Obstetrical Society and Council of University Chairs of Obstetrics and Gynecology statement. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 129-130.	0.7	0
5	Be the change you wish to see: cultivating gender equity. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 334-335.	0.7	0
6	Gender Inequity in the United States Surgical Workforce. , 2021, , 178-194.		0
7	Contributions, Aspirations, and Challenges of Academic Specialist Divisions in Obstetrics and Gynecology. <i>Obstetrics and Gynecology</i> , 2021, 137, 374-375.	1.2	0
8	Oncogenic B-Myb Is Associated With Deregulation of the DREAM-Mediated Cell Cycle Gene Expression Program in High Grade Serous Ovarian Carcinoma Clinical Tumor Samples. <i>Frontiers in Oncology</i> , 2021, 11, 637193.	1.3	6
9	Improving The Quality of Care for Persons With Advanced Epithelial Ovarian Cancer. <i>Oncology Issues</i> , 2021, 36, 36-48.	0.0	1
10	Surgery as women's work: gender in presentations at gynecologic conferences. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 454-455.	0.7	2
11	Professional Address during Obstetrics and Gynecology Grand Rounds Introductions: Setting the Stage, Setting the Standard. <i>Journal of Surgical Education</i> , 2021, 78, 1930-1937.	1.2	1
12	Body Image, Sexuality, and Sexual Functioning in Women With Gynecologic Cancer. <i>Cancer Nursing</i> , 2021, 44, E252-E286.	0.7	13
13	Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer. <i>Journal of Surgical Research</i> , 2020, 246, 34-41.	0.8	15
14	Distant recurrence in a patient with polyp-confined stage IA serous endometrial carcinoma treated with adjuvant chemotherapy: A case report and review of literature. <i>Gynecologic Oncology Reports</i> , 2020, 31, 100512.	0.3	5
15	Body Image, Sexuality, and Sexual Functioning in Cervical and Endometrial Cancer: Interrelationships and Women's Experiences. <i>Sexuality and Disability</i> , 2020, 38, 389-403.	0.4	5
16	A global care package for women: Gender-neutral human papillomavirus eradication. <i>Cancer</i> , 2020, 126, 4660-4663.	2.0	0
17	Leading from Behind: Paucity of gender equity statements and policies among professional surgical societies. <i>American Journal of Surgery</i> , 2020, 220, 1132-1135.	0.9	5
18	Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. <i>Cancer</i> , 2020, 126, 4948-4956.	2.0	37

#	ARTICLE	IF	CITATIONS
19	Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference. <i>Obstetrics and Gynecology</i> , 2020, 136, 635-635.	1.2	0
20	Has a critical mass of women resulted in gender equity in gynecologic surgery?. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 665-673.	0.7	36
21	Reducing Disparities in Receipt of Genetic Counseling for Underserved Women at Risk of Hereditary Breast and Ovarian Cancer. <i>Journal of Women's Health</i> , 2020, 29, 1131-1135.	1.5	14
22	Response Regarding: Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer. <i>Journal of Surgical Research</i> , 2020, 255, 652.	0.8	0
23	The Current Status of Women in Surgery. <i>JAMA Surgery</i> , 2020, 155, 876.	2.2	127
24	Take me to your leader: Reporting structures and equity in academic gynecologic oncology. <i>Gynecologic Oncology</i> , 2020, 157, 759-764.	0.6	14
25	A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6010-6010.	0.8	24
26	Gender Inequity in the United States Surgical Workforce. <i>Advances in Medical Education, Research, and Ethics</i> , 2020, , 252-269.	0.1	0
27	Reproductive health care across the lifecourse of the female cancer patient. <i>Supportive Care in Cancer</i> , 2019, 27, 23-32.	1.0	8
28	Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants. <i>Supportive Care in Cancer</i> , 2019, 27, 531-538.	1.0	11
29	Awareness and acceptability of population-based screening for pathogenic BRCA variants: Do race and ethnicity matter?. <i>Gynecologic Oncology</i> , 2019, 154, 383-387.	0.6	12
30	Surgical recommendations in the era of personalized medicine: What can we learn from patient preferences?. <i>Cancer</i> , 2019, 125, 4367-4370.	2.0	0
31	Co-occurring substance use disorder: The impact on treatment adherence in women with locally advanced cervical cancer. <i>Gynecologic Oncology Reports</i> , 2019, 28, 116-119.	0.3	4
32	Personal Reflections on Gynecologic Oncology and Its Future. <i>Obstetrics and Gynecology</i> , 2019, 133, 1255-1258.	1.2	5
33	Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. <i>Scientific Reports</i> , 2019, 9, 18882.	1.6	33
34	Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876. <i>Cancers</i> , 2019, 11, 33.	1.7	87
35	The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions. <i>Cancer</i> , 2019, 125, 499-514.	2.0	18
36	Hysterectomy-corrected rates of endometrial cancer among women younger than age 50 in the United States. <i>Cancer Causes and Control</i> , 2018, 29, 427-433.	0.8	19

#	ARTICLE	IF	CITATIONS
37	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report. <i>Gynecologic Oncology</i> , 2018, 149, 442-446.	0.6	14
38	A contemporary framework of health equity applied to gynecologic cancer care: A Society of Gynecologic Oncology evidenced-based review. <i>Gynecologic Oncology</i> , 2018, 149, 70-77.	0.6	55
39	Treatment-Related Radiation Toxicity Among Cervical Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1387-1393.	1.2	9
40	Narcotics reduction, quality and safety in gynecologic oncology surgery in the first year of enhanced recovery after surgery protocol implementation. <i>Gynecologic Oncology</i> , 2018, 149, 554-559.	0.6	38
41	Fatty acid oxidation: An emerging facet of metabolic transformation in cancer. <i>Cancer Letters</i> , 2018, 435, 92-100.	3.2	279
42	A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. <i>Gynecologic Oncology</i> , 2017, 144, 486-490.	0.6	47
43	The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations. <i>Gynecologic Oncology</i> , 2017, 145, 185-191.	0.6	4
44	Ovarian Cancer Prevention in High-risk Women. <i>Clinical Obstetrics and Gynecology</i> , 2017, 60, 738-757.	0.6	25
45	Outcomes Associated With a Five-Point Surgical Site Infection Prevention Bundle in Women Undergoing Surgery for Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2017, 130, 756-764.	1.2	36
46	The Utility of Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1416-1421.	1.2	16
47	Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival. <i>European Journal of Cancer</i> , 2017, 87, 182-188.	1.3	14
48	Uterine Sarcoma: Modern Treatment Paradigms. <i>Current Obstetrics and Gynecology Reports</i> , 2017, 6, 290-297.	0.3	0
49	Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future. <i>Frontiers in Oncology</i> , 2017, 7, 177.	1.3	59
50	Editorial: Cancer Care Delivery and Women's Health: Beyond the Patient and Provider Relationship. <i>Frontiers in Oncology</i> , 2017, 7, 213.	1.3	0
51	The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years. <i>Frontiers in Oncology</i> , 2016, 6, 63.	1.3	37
52	The End of the Hysterectomy Epidemic and Endometrial Cancer Incidence: What Are the Unintended Consequences of Declining Hysterectomy Rates?. <i>Frontiers in Oncology</i> , 2016, 6, 89.	1.3	40
53	Reducing Overtreatment in Gynecologic Oncology: The Case for Less in Endometrial and Ovarian Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 118.	1.3	7
54	Endometrial cancer: Not your grandmother's cancer. <i>Cancer</i> , 2016, 122, 2787-2798.	2.0	132

#	ARTICLE	IF	CITATIONS
55	VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. <i>Clinical Cancer Research</i> , 2016, 22, 4249-4258.	3.2	28
56	Unplanned 30-day hospital readmission as a quality measure in gynecologic oncology. <i>Gynecologic Oncology</i> , 2016, 143, 604-610.	0.6	31
57	The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2016, 143, 611-616.	0.6	30
58	Reducing overtreatment: A comparison of lymph node assessment strategies for endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 143, 281-286.	0.6	38
59	Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. <i>Gynecologic Oncology</i> , 2016, 143, 460-465.	0.6	79
60	Disparities in Surgical Care Among Women With Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2016, 128, 526-534.	1.2	38
61	The Use of "Optimal Cytoreduction" Nomenclature in Ovarian Cancer Literature: Can We Move Toward a More Optimal Classification System?. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1421-1427.	1.2	8
62	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , 2016, 9, 713-720.	0.7	7
63	Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 199-207.	1.2	32
64	National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. <i>Supportive Care in Cancer</i> , 2016, 24, 1439-1447.	1.0	86
65	Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers. <i>Cancer</i> , 2015, 121, 3395-3402.	2.0	10
66	Trends in Relative Survival for Ovarian Cancer From 1975-2011. <i>Obstetrics and Gynecology</i> , 2015, 126, 898.	1.2	4
67	Economic and Survival Implications of Use of Electric Power Morcellation for Hysterectomy for Presumed Benign Gynecologic Disease. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv251.	3.0	14
68	A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis. <i>Clinical Cancer Research</i> , 2015, 21, 68-76.	3.2	65
69	Geographic disparities amongst patients with gynecologic malignancies at an urban NCI-designated cancer center. <i>Gynecologic Oncology</i> , 2015, 137, 497-502.	0.6	36
70	"Less is more": The harms of overtreatment in early ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 137, 191-192.	0.6	2
71	Black and White Women in Maryland Receive Different Treatment for Cervical Cancer. <i>PLoS ONE</i> , 2014, 9, e104344.	1.1	40
72	Breast Self-Awareness. <i>Obstetrics and Gynecology</i> , 2014, 123, 734-736.	1.2	12

#	ARTICLE	IF	CITATIONS
73	Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. <i>Gynecologic Oncology</i> , 2013, 129, 120-123.	0.6	13
74	Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. <i>Gynecologic Oncology</i> , 2012, 127, 316-320.	0.6	18
75	Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. <i>Gynecologic Oncology</i> , 2012, 125, 19-24.	0.6	93
76	The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2011, 121, 218-223.	0.6	9
77	Assessing gynecologic and breast cancer survivors' sexual health care needs. <i>Cancer</i> , 2011, 117, 2643-2651.	2.0	151
78	Subcutaneous Methylnaltrexone to Restore Postoperative Bowel Function in a Long-Term Opiate User. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 308-310.	1.2	7
79	A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. <i>Gynecologic Oncology</i> , 2010, 117, 473-476.	0.6	67
80	Abstract B197: Phase II, single-arm study of tasisulam-sodium (LY573636-sodium) as 2nd-4th line therapy for platinum resistant ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, B197-B197.	1.9	4
81	Is Body Mass Index an Independent Risk Factor of Survival Among Patients With Endometrial Cancer?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 8-14.	0.6	46
82	Dysplastic endocervical curettings: a predictor of cervical squamous cell carcinoma. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 196, 469.e1-469.e4.	0.7	8
83	Type 2 11 ^β -hydroxysteroid dehydrogenase activity in human ovarian cancer. <i>Steroids</i> , 2006, 71, 1019-1023.	0.8	9